Rova-T对比安慰剂用于广泛期小细胞肺癌一线含铂化疗后维持治疗的III期MERU研究
MERU研究为III期随机双盲安慰剂对照试验,纳入一线含铂化疗四周期后无进展的广泛期小细胞肺癌患者,1:1随机接受Rova-T 0.3 mg/kg或安慰剂。在DLL3高表达亚组无效性分析中,OS风险比为1.07(95%CI 0.84-1.36),中位OS分别为8.5和9.8个月,无效性标准已满足。研究者评估的PFS方面Rova-T显著优于安慰剂(4.0 vs 1.4个月,HR=0.48,p<0.001),但因缺乏生存获益研究提前终止。
要点
- DLL3高表达亚组中Rova-T组OS无获益,中位OS 8.5 vs 9.8个月,HR=1.07。
- 研究者评估PFS显著改善(4.0 vs 1.4个月,HR=0.48,p<0.001),但中心评估未进行。
- Rova-T特有毒性包括胸腔积液、心包积液、光敏反应和外周水肿。
核心结论
- Rova-T作为广泛期小细胞肺癌一线化疗后维持治疗未显示生存获益,研究因无效性提前终止。
研究设计与样本
- MERU为III期随机、双盲、安慰剂对照研究,共随机748例一线含铂化疗四周期后无进展的广泛期小细胞肺癌患者。
- 患者按1:1随机接受Rova-T 0.3 mg/kg或安慰剂,每6周给药,每第三周期省略。
- 主要疗效终点为DLL3高表达肿瘤患者中中心影像评估委员会评估的PFS和OS。
主要发现
- 全部随机患者中位年龄64岁,78%为TNM IV期。
- DLL3高表达亚组无效性分析中,OS风险比为1.07(95%CI 0.84-1.36),倾向安慰剂组,中位OS Rova-T组8.5个月、安慰剂组9.8个月,无效性标准已满足。
- 研究者评估的PFS方面,Rova-T显著优于安慰剂(4.0 vs 1.4个月,HR=0.48,p<0.001)。
- Rova-T组任何级别不良事件(≥20%)包括胸腔积液(27%)、食欲下降(27%)、外周水肿(26%)、光敏反应(25%)、疲劳(25%)、恶心(22%)和呼吸困难(21%)。
关键数值与推荐
- Rova-T剂量为0.3 mg/kg,每6周一次,每第三周期省略。
- DLL3高表达亚组OS的HR为1.07(95%CI 0.84-1.36)。
- 研究者评估PFS的HR为0.48(p<0.001),中位PFS 4.0 vs 1.4个月。
临床怎么用
- Rova-T不推荐用于广泛期小细胞肺癌一线化疗后的维持治疗。
- 临床需警惕Rova-T相关胸腔积液、心包积液、光敏反应及外周水肿等特有毒性。
局限性
- 研究因无效性提前终止,中心影像评估委员会对PFS的评估未进行。
- OS无效性分析基于DLL3高表达亚组,全文未报告该亚组具体样本量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate targeting DLL3, an atypical Notch ligand expressed in SCLC tumors. We evaluated the efficacy of Rova-T versus placebo as maintenance therapy in patients with extensive-stage-SCLC after platinum-based chemotherapy. METHODS: MERU was a phase 3 randomized, double-blinded, placebo-controlled study. Patients without disease progression after four cycles of platinum-based, front-line chemotherapy were randomized in a 1:1 ratio to receive 0.3 mg/kg Rova-T or placebo (every 6 wk, omitted every third cycle). Primary efficacy end points were progression-free survival (PFS) evaluated by the Central Radiographic Assessment Committee and overall survival (OS) in patients with DLL3-high tumors. RESULTS: Median age of all randomized patients (N = 748) was 64 years; 78% had TNM stage IV disease. At futility analysis of the subset with DLL3-high tumors, the hazard ratio for OS was 1.07 (95% confidence interval: 0.84-1.36) favoring the placebo arm, with median OS of 8.5 and 9.8 months in the Rova-T and placebo arms, respectively; futility criteria were met. Rova-T significantly improved PFS versus placebo by investigator assessment (4.0 versus 1.4 mo, hazard ratio = 0.48, p < 0.001). Any-grade adverse events (≥20%) in the Rova-T arm were pleural effusion (27%), decreased appetite (27%), peripheral edema (26%), photosensitivity reaction (25%), fatigue (25%), nausea (22%), and dyspnea (21%). CONCLUSIONS: Because of the lack of survival benefit in the Rova-T arm, the study did not meet its primary end point and was terminated early. As a result, the Central Radiographic Assessment Committee evaluation of PFS was not performed. The frequency of grade greater than or equal to 3 and drug-related toxicities were higher with Rova-T versus placebo. Rova-T was associated with unique toxicities, such as pleural and pericardial effusions, photosensitivity reaction, and peripheral edema, which should be carefully considered in the population with extensive-stage-SCLC.
引用
- Johnson ML, Zvirbule Z, Laktionov K, et al. Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study. J Thorac Oncol. 2021. PMID: 33823285. doi:10.1016/j.jtho.2021.03.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。